NCT00407056

Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis

Phase 3 Open-Labeled Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Severe Anterior Uveitis (Including Panuveitis).

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 20 (planned)
• Sponsor: Sirion Therapeutics, Inc. · Industry
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this phase 3 open-labeled study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of severe uveitis.

Detailed description

The objective of this phase 3 study is to assess the efficacy and safety of 0.05% difluprednate ophthalmic emulsion in patients with severe endogenous anterior uveitis with an open-labeled, no-controlled and no-randomized design.

Conditions

• Uveitis
• Panuveitis

Interventions

Type	Name	Description
DRUG	Difluprednate Ophthalmic Emulsion

Timeline

• Start date: 2002-08-01
• Completion: 2003-06-01
• First posted: 2006-12-04
• Last updated: 2006-12-04